Pcn81 - Budget Impact Analysis of Cdk4/6 Inhibitors for the First Line Theraphy of Hr-Positive Her2-Negative Advanced Breast Cancer in the Russian Federation
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.163
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV